Document |
Document Title |
WO/2022/166720A1 |
Provided is a fusion protein, comprising a protein having a hydrophobic region, a peptide linker, a protein fusion receptor. The peptide linker links the protein having a hydrophobic region to the protein fusion receptor. The protein fus...
|
WO/2022/163041A1 |
Provided are: an indole-structure-selective reaction agent and an indole-structure-selective crosslinking agent which are capable of selectively modifying, under mild conditions, an indole structure of a molecule (e.g., tryptophan) conta...
|
WO/2022/155704A1 |
Disclosed are polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. More particularly, the invention provides peptide mimetics of PD-L1...
|
WO/2022/158497A1 |
In this invention, a hybridoma is prepared using, as the antigen, a protein with its secretion signal added to the receptor-binding domain (RBD, positions 319-589) of SARS-CoV-2 spike protein and G196 tag sequence (DLVPR) with His6 seque...
|
WO/2022/153898A1 |
Disclosed are insoluble particles comprising a particulate carrier and an antibody to a target antigen, said antibody being carried on the particulate carrier, wherein the C-terminal amino acid in a heavy chain of the antibody is lysine.
|
WO/2022/138718A1 |
The purpose of the present invention is to provide a polypeptide, which has excellent alkali stability and allows the elution of immunoglobulin or a fragment of the same, which has been bound thereto, in a weakly acidic region, by modify...
|
WO/2022/138758A1 |
Insoluble particles containing a granular carrier and an antibody to a target antigen carried on the granular carrier, no sugar chain being bonded to the heavy chain of the antibody.
|
WO/2022/138984A1 |
The present invention provides a neurite outgrowth promoter for promoting neurite growth on nerve cells of a postnatal mammalian individual for use in a condition in which an effective amount of a glial cell-derived neurotrophic factor (...
|
WO/2022/127326A1 |
Disclosed in the present invention are a protein and multi-stage porous metal-organic framework complex, a preparation method therefor, and an application thereof, relating to the technical field of biological material preparation. In th...
|
WO/2022/123054A1 |
The present invention relates to a method of making a composite material. The method comprises: a) providing a dehydrated protein-polymer surfactant conjugate (PPSC); b) heating the dehydrated PPSC above its annealing temperature, to a P...
|
WO/2022/115791A1 |
This invention relates to the compositions and methods for labeling antibodies and other proteins and targeting agents with a helical bundle protein that is functionalized with cargo. Cargos can include but are not limited to fluorescent...
|
WO/2022/103793A1 |
The present disclosure relates to proteins comprising a SARS-CoV-2 nucleoprotein- binding domain for detection of SARS-CoV-2, methods, compositions and kits thereof.
|
WO/2022/097500A1 |
A protein or peptide crosslinking agent which is represented by formula (I). [In the formula, A is a hydrogen atom, a C1-6 alkyl group which may be substituted with a phenyl group or a halogen atom, or a phenyl group.]
|
WO/2022/087804A1 |
Provided are a puromycin linker and an application thereof in synthesis of an in-vitro nucleic acid displayed peptide. The puromycin linker is a modified and unbranched single-stranded DNA; the single-stranded DNA comprises a first stret...
|
WO/2022/080486A1 |
The present invention addresses the problem of providing a polypeptide with further reduced binding properties with respect to D-biotin, and which strongly binds to L-biotin. Provided is a polypeptide belonging to the avidin-streptavidin...
|
WO/2022/073404A1 |
Provided is a fusion protein for a biosensing element; the fusion protein comprises glucose oxidase (GOD) and a carbohydrate-binding module (CBM); and the GOD is linked to the CBM by means of a linker peptide. The biosensing element spec...
|
WO/2022/074402A1 |
There is described a nanoparticle comprising one or more peptides having a sequence comprising the motif GLLxLLxLLLxAAG, wherein each x is independently selected from arginine (R), histidine (H), lysine (K), aspartic acid (D) or glutamic...
|
WO/2022/074380A1 |
The present invention relates to new synthetically generated carboxysome shells, shells encapsulating selected catalytically active enzymes, cells including the shells and methods of making the shells and methods of encapsulation. The in...
|
WO/2022/071849A1 |
The present application relates to a matrix for selective binding of at least one component from a body fluid, the matrix having a porous structure; wherein a peptide is covalently attached to the matrix via a linker; and wherein the mat...
|
WO/2022/067446A1 |
Disclosed is a proteolipid vesicle (PLV) for delivering a therapeutic cargo, such as nucleic acids, polypeptides and molecules, to a cell, the proteolipid vesicle having a lipid nanoparticle comprising one or more ionizable lipids and on...
|
WO/2022/069768A1 |
The invention relates to a new combinations of boron compounds and adjuvants and compositions thereof, suitable for use in a method to induce myotube formation and suppress cell mortality in a mammal in need thereof and for the treatment...
|
WO/2022/063892A1 |
The present invention provides a compound for the sequestration of undesirable neutralizing antibodies against viral vectors (as used in vaccines and in gene therapy) in a patient. The compound comprises an inert biopolymer scaffold and ...
|
WO/2022/063879A1 |
The present invention provides a compound for the sequestration of undesirable antibodies (e.g. related to an autoimmune disease) in a patient. The compound comprises an inert biopolymer scaffold, which is an anti-CD163 antibody or GD163...
|
WO/2022/063887A1 |
The present invention provides a compound for the sequestration of undesirable antibodies associated with hemophilia A, in particular when treated by factor VIII replacement therapy. The compound comprises a biopolymer scaffold and at le...
|
WO/2022/063882A1 |
The present invention provides a compound for the sequestration of undesirable antibodies associated with an autoantibody-mediated condition, such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), postural orthostatic tachy...
|
WO/2022/065052A1 |
Provided is a capture antibody which is immobilized on a solid-phase carrier and used for capturing a detection target substance, wherein at least a portion of a functional group of a first antibody having a specific binding activity to ...
|
WO/2022/063880A1 |
The present invention provides a compound for the sequestration of anti human muscle nicotinic acetylcholine receptor (AChR) autoantibodies, which are involved in the pathogenesis of MG. The compound comprises an inert biopolymer scaffol...
|
WO/2022/055993A1 |
Methods of treating irritable bowel syndrome (IBS) include the administration of an effective amount of an anti-microbial decapeptide NH2-Lys-Lys-Val-Val-Phe-Trp-Val-Lys-Phe-Lys-CO NH2 (SEQ ID NO 1) (KSL-W).
|
WO/2022/053844A1 |
The present invention provides a nanostructure (5) for lysis of a pathogenic bacteria in mammals. Said nanostructure (5) comprises one or more antimicrobial components (3) loaded into one or more carrier components (4) forming a core por...
|
WO/2022/051457A1 |
The present disclosure provides non-naturally occurring beta barrel proteins as defined, self-complementing multipartite beta barrel proteins, uses of such proteins, and methods for designing such proteins.
|
WO/2022/049600A1 |
The present disclosure discloses a method for assessing T cell-specific immune response against SARS-CoV-2, comprising contacting one or more samples with a peptide pool to obtain a mixture, wherein the peptide pool comprises three to fi...
|
WO/2022/031376A1 |
The invention encompasses emulsomes coated with S-layer fusion proteins, pharmaceutical compositions and vaccines comprising the emulsomes, and methods of use thereof for immunizing a patient.
|
WO/2022/023461A1 |
A specific epitope has been identified in the present invention, which is herein used for detecting and/or quantifying autoantibodies against alpha-fetoprotein (AFP) in a biological sample, and consequently for the in vitro diagnosis of ...
|
WO/2022/016751A1 |
Provided are a molecular diagnosis and treatment formulation, a preparation method therefor and use thereof. The formulation comprises: (1) an effect component, i.e. a diagnostic compound and/or a drug for treating endometriosis; and (2)...
|
WO/2022/011466A1 |
There is provided a surface functionalized with cross linking groups adapted to receive antibodies and/or fragments thereof. The surface has an antibody binding biomolecule having a linker region which is covalently crosslinked to functi...
|
WO/2022/003674A1 |
Disclosed are peptides that specifically bind to neutrophils and uses thereof for neutrophil-targeted delivery of drugs or diagnostic agents in medical conditions including cancer as well as infectious, inflammatory and autoimmune diseas...
|
WO/2021/262625A1 |
Described are S-layer fusion proteins comprising a self-assembling domain of a S- layer protein and a viral spike protein or a fragment thereof, a pharmaceutical composition (such as a vaccine) comprising the S-layer fusion protein, and ...
|
WO/2021/254868A1 |
The present invention provides methods and tools to determine a serological signature of antibodies against SARS-CoV-2 from a biological sample of a subject. More particularly, a method is provided for the detection of antibodies against...
|
WO/2021/256674A1 |
The present invention relates to a method for increasing the stability of a target protein immobilized in a silica nanoparticle through salt treatment. The method of the present invention can be usefully utilized in, for example, bio-rel...
|
WO/2021/249433A1 |
A SpyCatcher peptide-modified carrier, a protein immobilizing carrier, and a protein immobilizing method. The method comprises: linking a SpyCatcher peptide to a carrier so as to obtain a SpyCatcher peptide-modified carrier; and then bas...
|
WO/2021/246620A1 |
The present invention relates to a metal compound having phase transformation, and a preparation method thereof, the metal compound being expressed by {M2+(OH)y(O)z}A(2-x')·nH2O and being 60-99 vol% amorphous.
|
WO/2015/107335A9 |
The present invention provides a method for the functionalization of a polymeric surface with a protein by physical adsorption. The method enables a membrane spanning protein to be used as an anchor for proteins and/or peptides for displ...
|
WO/2021/241528A1 |
The present invention pertains to a method for using a nucleic acid compound that contains a selectively cleavable site. Also, the present invention pertains to a DNA-encoded library, said DNA containing a selectively cleavable site, a c...
|
WO/2021/243203A1 |
Provided herein are methods of producing a distinct bilayer culture of retinal epithelial cells (RPE) with photoreceptor cells and/or photoreceptor precursor cells (PR/PRP). Further provided herein is a therapy comprising transplantation...
|
WO/2021/237280A1 |
This invention relates to polypeptides, including variants of inhibin, and related therapeutics and compositions. Further, the invention relates to the use in the treatment or prevention of conditions associated with reduced levels of in...
|
WO/2021/241446A1 |
A method for detecting a target molecule in a specimen, comprising: a (target molecule)-(labelled binding molecule)-(capturing molecule) complex formation step for reacting the target molecule in the specimen, a capture molecule that is ...
|
WO/2021/235767A1 |
The present invention relates to a method for obtaining a collagen peptide from starfish, an elastic liposome comprising the starfish-derived collagen peptide, and a cosmetic composition comprising same. According to the present inventio...
|
WO/2021/234579A1 |
Provided is a recombinant polypeptide comprising a resistin trimerization domain and a polypeptide of interest. Further provided is an expression vector encoding the recombinant polypeptide and a method of expressing the recombinant poly...
|
WO/2021/224833A1 |
The present invention relates to a bio-nanocompound including: metal oxide particles as a substrate; an amino organosilane as a bonding agent; a dialdehyde as a cross-linking agent; and a nucleating agent that uses the nucleating activit...
|
WO/2021/224375A1 |
The present invention relates to a method of producing a composition, the composition comprising a solid carrier, a functional constituent and a protective layer to protect the functional constituent.
|